AI assistant
Emergent BioSolutions Inc. — Director's Dealing 2022
Feb 25, 2022
32870_dirs_2022-02-24_4533a6d7-3bd2-43bb-9819-994375eeeb53.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Emergent BioSolutions Inc. (EBS)
CIK: 0001367644
Period of Report: 2022-02-22
Reporting Person: SARAN ATUL (EVP, Corp Dev, GC & Secretary)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-02-22 | Common Stock | A | 1836 | — | Acquired | 46596 | Direct |
| 2022-02-22 | Common Stock | F | 2084 | $42.23 | Disposed | 44512 | Direct |
Footnotes
F1: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted net income as a percentage of total GAAP revenue for the 2021 fiscal year, as certified by the Compensation Committee following the performance period. On February 22, 2022, the final certification date, the Compensation Committee certified the achievement of the 2019-2021 PSUs at a payout factor of 136.14% of target resulting in the actual award of 6,917 shares of common stock, which is in excess of the 5,081 shares previously reported on February 28, 2019.
F2: Represents shares of common stock withheld to pay taxes.